Anticancer Properties of Zoledronic Acid

REFERENCES

• Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009
   Google Scholar
• Rosen, L.S.; Gordon, D.; Tchekmedyian, S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; de Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J.J. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003, 21, 3150–3157.
   PubMed Web of Science ®Google Scholar
• Rosen, L.S.; Gordon, D.; Tchekmedyian, N.S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; De Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung cancer and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100, 2613–2621.
   PubMed Web of Science ®Google Scholar
• Green, J.R. Bisphosphonates: preclinical review. Oncologist 2004. 9(suppl 4), S3–S13.
   Google Scholar
• Hirbe, A.C.; Roelofs, A.J.; Floyd, D.H.; Deng, H.; Becker, S.N.; Lanigan, L.G.; Apicelli, A.J.; Xu, Z.; Prior, J.L.; Eagleton, M.C.; Piwnica-Worms, D.; Rogers, M.J.; Weilbaecher, K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009, 44, 908–916.
   PubMed Web of Science ®Google Scholar
• Hiraga, T.; Williams, P.J.; Ueda, A.; Tamura, D.; Yoneda, T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10, 4559–4567.
   PubMed Web of Science ®Google Scholar
• Giraudo, E.; Inoue, M.; Hanahan, D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114, 623–633.
   PubMed Web of Science ®Google Scholar
• Matsumoto, S.; Kimura, S.; Segawa, H.; Kuroda, J.; Yuasa, T.; Sato, K.; Nogawa, M.; Tanaka, F.; Maekawa, T.; Wada, H. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005, 47, 31–39.
   PubMed Web of Science ®Google Scholar
• Ory, B.; Heymann, M.F.; Kamijo, A.; Gouin, F.; Heymann, D.; Redini, F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104, 2522–2529.
   PubMed Web of Science ®Google Scholar
• Wakchoure, S.; Merrell, M.A.; Aldrich, W.; Millender-Swain, T.; Harris, K.W.; Triozzi, P.; Selander, K.S. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006, 12, 2862–2868.
   PubMed Web of Science ®Google Scholar
• Melani, C.; Sangaletti, S.; Barazzetta, F.M.; Werb, Z.; Colombo, M.P. Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67, 11438–11446.
   PubMed Web of Science ®Google Scholar
• Stathopoulos, G.T.; Moschos, C.; Loutrari, H.; Kollintza, A.; Psallidas, I.; Karabela, S.; Magkouta, S.; Zhou, Z.; Papiris, S.A.; Roussos, C.; Kalomenidis, I. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008, 178, 50–59.
   PubMed Web of Science ®Google Scholar
• Bäckman, U.; Svensson, A.; Christofferson, R.H.; Azarbayjani, F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 2008, 28, 1551–1557.
   PubMed Web of Science ®Google Scholar
• Li, Y.Y.; Chang, J.W.C.; Chou, W.C.; Liaw, C.C.; Wang, H.M.; Huang, J.S.; Wang, C.H.; Yeh, K.Y. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008, 59, 180–191.
   PubMed Web of Science ®Google Scholar
• Ottewell, P.D.; Mönkkönen, H.; Jones, M.; Lefley, D.V.; Coleman, R.E.; Holen, I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100, 1167–1178.
   PubMed Web of Science ®Google Scholar
• Lu, S.; Zhang, J.; Zhou, Z.; Liao, M.L.; He, W.Z.; Zhou, X.Y.; Li, Z.M.; Xiang, J.Q.; Wang, J.J.; Chen, H.Q. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 2008, 20, 581–587.
   PubMed Web of Science ®Google Scholar
• Chang, J.W.C.; Hsieh, J.J.; Shen, Y.C.; Yeh, K.Y.; Wang, C.H.; Li, Y.Y.; Hsu, T. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. Cancer Lett 2009, 278, 17–26.
   PubMed Web of Science ®Google Scholar
• Coscia, M.; Quaglino, E.; Iezzi, M.; Curcio, C.; Pantaleoni, F.; Riganti, C.; Holen, I.; Mönkkönen, H.; Boccadoro, M.; Forni, G.; Musiani, P.; Bosia, A.; Cavallo, F.; Massaia, M. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2009 Oct 10 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ottewell, P.D.; Lefley, D.V.; Cross, S.S.; Evans, C.A.; Coleman, R.E.; Holen, I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2009, 126, 522–532.
   Web of Science ®Google Scholar
• Mundy, G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2, 584–593.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis, K.; Boutsikou, E.; Zarogoulidis, P.; Eleftheriadou, E.; Kontakiotis, T.; Lithoxopoulou, H.; Tzanakakis, G.; Kanakis, I.; Karamanos, N.K. The impact of zoledronic aid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009, 125, 1705–1709.
   PubMed Web of Science ®Google Scholar
• Avilés, A.; Nambo, M.J.; Neri, N.; Castañeda, C.; Cleto, S.; Huerta-Guzmán, J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24, 227–230.
   PubMed Web of Science ®Google Scholar
• Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Pöstlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrik, M.; Fitzal, F.; Stierer, M.; Rücklinger, E.; Greil, R. ABCSG-12 Trial Investigators; Marth, C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360, 679–691.
   PubMed Web of Science ®Google Scholar
• Legay, F.; Gauron, S.; Deckert, F.; Gosset, G.; Pfaar, U.; Ravera, C.; Wiegand, H.; Schran, H. Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. J Pharm Biomed Anal 2002, 30, 897–911.
   PubMed Web of Science ®Google Scholar
• Leu, C.T.; Luegmayr, E.; Freedman, L.P.; Rodan, G.A.; Reszka, A.A. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006, 38, 628–36.
   PubMed Web of Science ®Google Scholar
• Chen, T.; Berenson, J.; Vescio, R.; Swift, R.; Gilchick, A.; Goodin, S.; LoRusso, P.; Ma, P.; Ravera, C.; Deckert, F.; Schran, H.; Seaman, J.; Skerjanec, A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42, 1228–1236.
   PubMed Web of Science ®Google Scholar
• Weiss, H.M.; Pfaar, U.; Schweitzer, A.; Wiegand, H.; Skerjanec, A.; Schran, H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008, 36, 2043–2049.
   PubMed Web of Science ®Google Scholar
• Nancollas, G.H.; Tang, R.; Phipps, R.J.; Henneman, Z.; Gulde, S.; Wu, W.; Mangood, A.; Russell, R.G.; Ebetino, F.H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38, 617–627.
   PubMed Web of Science ®Google Scholar
• Roelofs, A.J.; Jauhiainen, M.; Mönkkönen, H.; Rogers, M.J.; Mönkkönen, J.; Thompson, K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2009, 144, 245–250.
   PubMed Web of Science ®Google Scholar
• Thompson, K.; Rogers, M.J.; Coxon, F.P.; Crockett, J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 69, 1624–1632.
   PubMed Web of Science ®Google Scholar
• Winter, M.C.; Holen, I.; Coleman, R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34, 453–475.
   PubMed Web of Science ®Google Scholar
• Gober, H.J.; Kistowska, M.; Angman, L.; Jenö, P.; Mori, L.; De Libero, G. Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003, 197, 163–168.
   PubMed Web of Science ®Google Scholar
• Martino, A.; Poccia, F. Gamma delta T cells and dendritic cells: close partners and biological adjuvants for new therapies. Curr Mol Med 2007, 7, 658–673.
   PubMed Web of Science ®Google Scholar
• Benzaid, I.; Mönkkönen, H.; Stresing, V.; Bonnelye, E.; Green, J.; Mönkkönen, J.; Touraine, J.; Clézardin, P. Zoledronic acid-induced IPP/Apppl (phosphoantigen) accumulation in human breast cancer cells correlates with Vgamma9Vdelta2 T-cell mediated cancer cell death in vitro and in vivo [abstract S9]. Bone 2010, 47:S266–S267.
   Web of Science ®Google Scholar
• Räikkönen, J.; Crockett, J.C.; Rogers, M.J.; Mönkkönen, H.; Auriola, S.; Mönkkönen, J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009, 157, 427–435.
   PubMed Web of Science ®Google Scholar
• Stresing, V.; Daubiné, F.; Benzaid, I.; Mönkkönen, H.; Clézardin, P. Bisphosphonates in cancer therapy. Cancer Lett 2007, 257, 16–35.
   PubMed Web of Science ®Google Scholar
• Dunford, J.E.; Thompson, K.; Coxon, F.P.; Luckman, S.P.; Hahn, F.M.; Poulter, C.D.; Ebetino, F.H.; Rogers, M.J. Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296, 235–242.
   PubMed Web of Science ®Google Scholar
• Dunford, J.E.; Kwaasi, A.A.; Rogers, M.J.; Barnett, B.L.; Ebetino, F.H.; Russell, R.G.; Oppermann, U.; Kavanagh, K.L. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008, 51, 2187–2195.
   PubMed Web of Science ®Google Scholar
• Guo, R.T.; Cao, R.; Liang, P.H.; Ko, T.P.; Chang, T.H.; Hudock, M.P.; Jeng, W.Y.; Chen, C.K.; Zhang, Y.; Song, Y.; Kuo, C.J.; Yin, F.; Oldfield, E.; Wang, A.H. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A 2007, 104, 10022–10027.
   PubMed Web of Science ®Google Scholar
• Bivi, N.; Romanello, M.; Harrison, R.; Clarke, I.; Hoyle, D.C.; Moro, L.; Ortolani, F.; Bonetti, A.; Quadrifoglio, F.; Tell, G.; Delneri, D. Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. Genome Biol 2009, 10, R93.
   PubMedGoogle Scholar
• Mönkkönen, H.; Kuokkanen, J.; Holen, I.; Evans, A.; Lefley, D.V.; Jauhiainen, M.; Auriola, S.; Mönkkönen, J. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008, 19, 391–399.
   PubMed Web of Science ®Google Scholar
• Fromigue, O.; Lagneaux, L.; Body, J.J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000, 15, 2211–2221.
   PubMed Web of Science ®Google Scholar
• Senaratne, S.G.; Pirianov, G.; Mansi, J.L.; Arnett, T.R.; Colston, K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82, 1459–1468.
   PubMed Web of Science ®Google Scholar
• Jagdev, S.P.; Coleman, R.E.; Shipman, C.M.; Rostami, H.A.; Croucher, P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, 84, 1126–1134.
   PubMed Web of Science ®Google Scholar
• Verdijk, R.; Franke, H.R.; Wolbers, F.; Vermes, I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007, 246, 308–312.
   PubMed Web of Science ®Google Scholar
• Ullén, A.; Schwarz, S.; Lennartsson, L.; Kalkner, K.M.; Sandstrom, P.; Costa, F.; Lennernas, B.; Linder, S.; Nilsson, S. Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 2009, 43, 98–103.
   PubMed Web of Science ®Google Scholar
• Karabulut, B.; Erten, C.; Gul, M.K.; Cengiz, E.; Karaca, B.; Kucukzeybek, Y.; Gorumlu, G.; Atmaca, H.; Uzunoglu, S.; Sanli, U.A.; Baran, Y.; Uslu, R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 2009, 33, 239–246.
   PubMed Web of Science ®Google Scholar
• Pickering, L.M.; Macdonald, C.D.; Coxon, J.P.; Mansi, J.L.; Colston, K.W. Zoledronic acid inhibits adhesion of breast cancer cells to protein matrices in a caspase dependent manner. Bone 2004, 34(suppl 1, abstr 38), S68–S69
   Google Scholar
• Garrioch, S.; Roelofs, A.J.; Ebetino, F.H.; Rogers, M.J. Prevention of breast cancer cell adhesion to bone in vitro by bisphosphonates is mediated by their inhibitory effect on protein prenylation. Bone 2006, 38(3 suppl 1, abstr 45), S59–S60.
   PubMed Web of Science ®Google Scholar
• Boissier, S.; Ferreras, M.; Peyruchaud, O.; Magnetto, S.; Ebetino, F.H.; Colombel, M.; Delmas, P.; Delaissé, J.M.; Clézardin, P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60, 2949–2954.
   PubMed Web of Science ®Google Scholar
• Koto, K.; Horie, N.; Kumura, S.; Murata, H.; Sakabe, T.; Matsui, T.; Watanabe, M.; Adachi, S.; Maekawa, T.; Fushiki, S.; Kubo, T. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastases in a murine osteosarcoma model. Cancer Lett 2009, 274, 271–278.
   PubMed Web of Science ®Google Scholar
• Denoyelle, C.; Hong, L.; Vannier, J.-P.; Soria, J.; Soria, C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by duel RhoA-dependent and -independent effects. Br J Cancer 2003, 88, 1631–1640.
   PubMed Web of Science ®Google Scholar
• Wood, J.; Bonjean, K.; Ruetz, S.; Bellahcène, A.; Devy, L.; Foidart, J.M.; Castronovo, V.; Green, J.R. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302, 1055–1061.
   PubMed Web of Science ®Google Scholar
• Yamada, J.; Tsuno, N.H.; Kitayama, J.; Tsuchiya, T.; Yoneyama, S.; Asakage, M.; Okaji, Y.; Shuno, Y.; Nishikawa, T.; Tanaka, J.; Takahashi, K.; Nagawa, H. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 2009, 151, 115–120.
   PubMed Web of Science ®Google Scholar
• Mantovani, A.; Schioppa, T.; Porta, C.; Allavena, P.; Sica, A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006, 25, 315–322.
   PubMed Web of Science ®Google Scholar
• Thompson, K.; Roelofs, A.J.; Jauhiainen, M.; Mönkkönen, H.; Mönkkönen, J.; Rogers, M.J. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol 2010, 658, 11–20.
   PubMed Web of Science ®Google Scholar
• Yuasa, T.; Kimura, S.; Ashihara, E.; Habuchi, T.; Maekawa, T. Zoledronic acid—a multiplicity of anti-cancer action. Curr Med Chem 2007, 14, 2126–2135.
   PubMed Web of Science ®Google Scholar
• Thompson, K.; Rogers, M.J. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19, 278–288.
   PubMed Web of Science ®Google Scholar
• Dieli, F.; Gebbia, N.; Poccia, F.; Caccamo, N.; Montesano, C.; Fulfaro, F.; Arcara, C.; Valerio, M.R.; Meraviglia, S.; Di Sano, C.; Sireci, G.; Salerno, A. Induction of gamma, delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102, 2310–2311.
   PubMed Web of Science ®Google Scholar
• Li, W.; Yamamoto, H.; Kubo, S.; Okamura, H. Modulation of innate immunity by IL-18. J Reprod Immunol 2009, 83, 101–105.
   PubMed Web of Science ®Google Scholar
• Sato, K.; Kimura, S.; Segawa, H.; Yokota, A.; Matsumoto, S.; Kuroda, J.; Nogawa, M.; Yuasa, T.; Kiyono, Y.; Wada, H.; Maekawa, T. Cytotoxic effects of gamma, delta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005, 116, 94–99.
   PubMed Web of Science ®Google Scholar
• Coxon, F.P.; Thompson, K.; Roelofs, A.J.; Ebetino, F.H.; Rogers, M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42, 848–860.
   PubMed Web of Science ®Google Scholar
• Shih, J.Y.; Yuan, A.; Chen, J.J.W.; Yang, P.C. Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2006, 2, 101–106.
   Google Scholar
• Daubiné, F.; Le Gall, C.; Gasser, J.; Green, J.; Clézardin, P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99, 322–330.
   PubMed Web of Science ®Google Scholar
• Neville-Webbe, H.L.; Rostami-Hodjegan, A.; Evans, C.A.; Coleman, R.E.; Holen, I. Sequence- and schedule-dependent enhancement of zoledronic acid induced by apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113, 364–371.
   PubMed Web of Science ®Google Scholar
• Neville-Webbe, H.L.; Evans, C.A.; Coleman, R.E.; Holen, I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 2006, 27, 92–103.
   PubMed Web of Science ®Google Scholar
• Neville-Webbe, H.L.; Coleman, R.E.; Holen, L. Combined effects of the bisphosphonate zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010, 102, 1010–1017.
   PubMed Web of Science ®Google Scholar
• Clyburn, R.D.; Reid, P.; Evans, C.A.; Lefley, D.V.; Holen, I. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 2010, 65, 969–978.
   PubMed Web of Science ®Google Scholar
• Witters, L.M.; Crispino, J.; Fraterrigo, T.; Green, J.; Lipton, A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003, 26, S92–S97.
   PubMed Web of Science ®Google Scholar
• Vogt, U.; Bielawski, K.P.; Bosse, U.; Schlotter, C.M. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/methotrexate/5-fluorouracil, epirubicin/ cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004, 12, 1109–1114.
   PubMed Web of Science ®Google Scholar
• Melisi, D.; Caputo, R.; Damiano, V.; Bianco, R.; Veneziani, B.M.; Bianco, A.R.; De Placido, S.; Ciardiello, F.; Tortora, G. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 2005, 12, 1051–1058.
   PubMed Web of Science ®Google Scholar
• Ottewell, P.D.; Woodward, J.K.; Lefley, D.V.; Evans, C.A.; Coleman, R.E.; Holen, I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009, 8, 2821–2832.
   PubMedGoogle Scholar
• Okamoto, K.; Tsurutani, J.; Terashima, M.; Okamoto, I.; Nakagawa, K. Zoledronic acid-induced regression of multiple metastases at nonskeletal sites. Ann Oncol 2009, 20 796–797.
   PubMed Web of Science ®Google Scholar
• Laggner, U.; Lopez, J.S.; Perera, G.; Warbey, V.S.; Sita-Lumsden, A.; O’Doherty, M.J.; Hayday, A.; Harries, M.; Nestle, F.O. Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy. Clin Immunol 2009, 131, 367–373.
   PubMed Web of Science ®Google Scholar
• Español, I.; Romagosa, V.; Berlanga, J.; Domingo, A.; Losa, F.; Heras, L.; Janáriz, J. Zoledronate-induced remission of actue panmyelosis with myelofibrosis. Eur J Haematol 2004, 73, 215–218.
   PubMed Web of Science ®Google Scholar
• Rack, B.; Jückstock, J.; Genss, E.M.; Schoberth, A.; Schindlbeck, C.; Strobl, B.; Heinrigs, M.; Rammael, G.; Zwingers, T.; Sommer, H.; Friese, K.; Janni, W. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30(5):1807–1813.
   PubMed Web of Science ®Google Scholar
• Aft, R.; Naughton, M.; Trinkaus, K.; Watson, M.; Ylagan, L.; Chavez-MacGregor, M.; Zhai, J.; Kuo, S.; Shannon, W.; Diemer, K.; Hermann, V.; Dietz, J.; Ali, A.; Ellis, M.; Weiss, P.; Eberlein, T.; Ma, C.; Fracasso, P.M.; Zoberi, I.; Taylor, M.; Gillanders, W.; Pluard, T.; Mortimer, J.; Weilbaecher, K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11(5):421–428.
   PubMed Web of Science ®Google Scholar
• Greenberg, S.; Park, J.W.; Melisko, M.E.; Goga, A.; Moasser, M.M.; Anderson, M.; Scott, J.H.; Petrillo, L.A.; Moore, D.H.; Rugo, H.S. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results [abstract 1002]. Presented at the 46th American Society of Clinical Oncology Meeting, Chicago, IL, June 4–8, 2010.
   Google Scholar
• Solomayer, E.F.; Gebauer, G.; Hirnle, P.; Janni, W.; Lück, H.-J.; Becker, S.; Huober, J.; Kraemer, B.; Wackwitz, B.; Fehm, T. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10–14, 2008 (abstr 2048).
   Google Scholar
• Abe, Y.; Muto, M.; Nieda, M.; Nakagawa, Y.; Nicol, A.; Kaneko, T.; Goto, S.; Yokokawa, K.; Suzuki, K. Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009, 37, 956–968.
   PubMed Web of Science ®Google Scholar
• Santini, D.; Martini, F.; Fratto, M.E.; Galluzzo, S.; Vincenzi, B.; Agrati, C.; Turchi, F.; Piacentini, P.; Rocci, L.; Manavalan, J.S.; Tonini, G.; Poccia, F. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58, 31–38.
   PubMed Web of Science ®Google Scholar
• Brufsky, A.; Harker, W.G.; Beck, J.T.; Carroll, R.; Jin, L.; Warsi, G.; Argonza-Aviles, E.; Ericson, S.; Perez, E.A. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in post-menopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10–13, 2009 (abstr 4083).
   Google Scholar
• Brufsky, A.; Bosserman, L.; Caradonna, R.; Haley, B.B.; Jones, C.M.; Moore, H.C.; Jin, L.; Warsi, G.M.; Ericson, S.G.; Perez, E.A. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9, 77–85.
   PubMed Web of Science ®Google Scholar
• Eidtmann, H.; de Boer, R.; Bundred, N.; Llombart-Cussac, A.; Davidson, N.; Neven, P.; von Micnkwitz, G.; Miller, J.; Schenk, N.; Coleman, R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010 May 5. [Epub ahead of print].
   Web of Science ®Google Scholar
• Brufsky, A.; Bundred, N.; Coleman, R.; Lambert-Falls, R.; Mena, R.; Hadji, P.; Jin, L.; Schenk, N.; Ericson, S.; Perez, E.A.; Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13, 503–514.
   PubMed Web of Science ®Google Scholar
• Frassoldati, A.; Brufsky, A.; Bundred, N.; Lambert-Falls, R.; Hadji, P.; Coleman, R. The effect of zoledronic acid on aromatase inhibitor (AI) associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months (MOS) integrated follow-up of the Z-FAST/ZO-FAST trials. Ann Oncol 2008, 19(suppl 8, abstr 185PD), viii78.
   Google Scholar
• Coleman, R.E.; Winter, M.C.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M.M.; Gil, M.; Ritchie, D.; Passos-Coelho, J.L.; Wheatley, D.; Burkinshaw, R.; Marshall, S.J.; Thorpe, H. on behalf of the AZURE (BIG01/04) Investigators. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response; exploratory revidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102, 1099–1105.
   PubMed Web of Science ®Google Scholar
• Winter, M.C.; Evans, A.; Holen, I.; Coleman, R.E. Anti-angiogenic potential of ZOL combined with neoadjuvant chemotherapy in invasive BC (ANZAC). Presented at the IX International Meeting on Cancer Induced Bone Disease, Arlington, VA, October 28–31, 2009 (abstr P67).
   Google Scholar
• Scagliotti, G.; Manegold, C.; de Marinis, F.; Engel-Riedel, W.; Albert, I.; Sallo, V.; Chen, Y.M.; Perez, J.R.; Kosmidis, P. Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer. Presented at the joint 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology, Berlin, Germany, September 20–24, 2009 (abstr P-9056).
   Google Scholar
• ClinicalTrials.gov. Clinical Trials. Gov List Results. http://clinicaltrials.gov/ct2/results?intr=%22zoledronic+acid%22. Accessed August 26, 2010.
   Google Scholar
• Morgan, G.; Davies, F.; Gregory, W.; Bell, S.E.; Szubert, A.; Navarro Coy, N.; Drayson, M.; Owen, R.G.; Jackson, G.H.; Child, J.A. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study [abstract 8021]. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4–8, 2010
   Google Scholar